Mesothelioma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BAP1 4
• PD-1 6
• TP53 0
• PD-L1 4
• YAP 0
• CDKN2A 0
• CTLA-4 2
• AXL 0
• B7-H3 0
• MDM2 0
• MET 0
• PRMT5 3
• VEGF 1
• AKT 0
• BRCA1 0
• EGFR 1
• EZH2 0
• FAK 0
• HMGB1 0
• NRF2 0
• PARP 0
• STAT3 0
• STK11 0
• TROP2 0
• AMPK 0
• ARID1A 1
• BRAF 0
• BRCA2 0
• CD30 0
• CD40 0
• CDK4/6 0
• GPC3 1
• IDH 0
• IL-17 0
• IL-6 0
• JNK 0
• LAG-3 1
• mTOR 0
• MUC1 0
• NTRK 1
• PI3K 0
• STING 0

EU-13 is a filter, not a ranking: it only narrows the list.

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

  NCT06654050· National Cancer Institute (NCI)· Updated 17 Mar 2026

  “The study is being withdrawn due to the CRADA with the company not being finalized”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

  NCT04431024· National Cancer Institute (NCI)· Source

• Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1

  NCT03830229· National Cancer Institute (NCI)· Source

• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

  NCT05960773· National Cancer Institute (NCI)· Source

• Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

  NCT06654050· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Organoids 3
• Mendelian Randomization Analysis 1
• Gene Expression Profiling 6
• Exome Sequencing 3
• Proteomics 8
• Mass Spectrometry 3
• Flow Cytometry 6
• Immunohistochemistry 26
• Xenograft Model Antitumor Assays 21
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 3
• Machine Learning 6
• Deep Learning 1
• Cohort Studies 10
• Genome-Wide Association Study 3

• Integrative Bioinformatics and Machine Learning Approaches for Biomarker and Pathway Discovery in Malignant Pleural Mesothelioma.

  Cancer Rep (Hoboken), Oct 2026

• Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma.

  Sci Rep, Jun 2026

• Targeting key proteins of pleural mesothelioma using plumbagin-indole-3-propionic acid ester: Insights from network pharmacology, molecular dynamics simulation and machine learning-based analysis.

  Comput Biol Chem, Dec 2025

• Near-infrared spectroscopy combined with machine learning for plasma-based discriminant diagnosis of malignant mesothelioma: a retrospective study.

  PeerJ, Dec 2025

• Cancer Risk Prediction Using Machine Learning for Supporting Early Cancer Diagnosis in Symptomatic Patients: A Systematic Review of Model Types.

  Cancer Med, Dec 2025

• Distant Metastatic Pattern and Its Prognostic Significance in Malignant Pleural Mesothelioma: A Population-Based Study Based on a Machine Learning Model.

  Clin Respir J, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.